Revance Therapeutics Inc (RVNC) Insider Cyril Allouche Sells 2,188 Shares of Stock

Share on StockTwits

Revance Therapeutics Inc (NASDAQ:RVNC) insider Cyril Allouche sold 2,188 shares of Revance Therapeutics stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $23.72, for a total value of $51,899.36. Following the transaction, the insider now owns 6,938 shares of the company’s stock, valued at $164,569.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

NASDAQ:RVNC traded down $0.54 during mid-day trading on Friday, hitting $23.46. 180,701 shares of the stock were exchanged, compared to its average volume of 204,329. Revance Therapeutics Inc has a fifty-two week low of $21.45 and a fifty-two week high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $0.04. The business had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $0.49 million. Revance Therapeutics had a negative return on equity of 61.45% and a negative net margin of 4,205.52%. As a group, equities research analysts forecast that Revance Therapeutics Inc will post -3.83 earnings per share for the current year.

RVNC has been the subject of several research analyst reports. BidaskClub upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. ValuEngine upgraded Revance Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 2nd. Zacks Investment Research downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Cantor Fitzgerald set a $50.00 target price on Revance Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Revance Therapeutics in a research note on Monday, September 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. Revance Therapeutics presently has a consensus rating of “Buy” and an average price target of $46.60.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in Revance Therapeutics by 9.0% during the 3rd quarter. BlackRock Inc. now owns 3,194,983 shares of the biopharmaceutical company’s stock worth $79,395,000 after purchasing an additional 263,003 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Revance Therapeutics by 26.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,464,617 shares of the biopharmaceutical company’s stock worth $61,245,000 after purchasing an additional 519,938 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Revance Therapeutics by 26.1% during the 3rd quarter. Alliancebernstein L.P. now owns 1,651,949 shares of the biopharmaceutical company’s stock worth $41,051,000 after purchasing an additional 341,896 shares during the last quarter. Fosun International Ltd lifted its holdings in Revance Therapeutics by 48.0% during the 2nd quarter. Fosun International Ltd now owns 472,532 shares of the biopharmaceutical company’s stock worth $12,971,000 after purchasing an additional 153,219 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Revance Therapeutics by 22.5% during the 2nd quarter. Northern Trust Corp now owns 415,856 shares of the biopharmaceutical company’s stock worth $11,415,000 after purchasing an additional 76,406 shares during the last quarter. 94.42% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first posted by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://weekherald.com/2018/11/10/revance-therapeutics-inc-rvnc-insider-cyril-allouche-sells-2188-shares-of-stock.html.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply